Dr. Steven A. Fischkoff on Access to TIL Treatment for Patients With Melanoma
Fischkoff says the goal of Lion Biotechnologies is to utilize a central manufacturing facility where medical professionals can submit tumor samples of their patients, and received the proper TIL-based treatment back from the manufacturing facility.
Steven A. Fischkoff, MD, chief medical officer, Lion Biotechnologies, Inc., discusses the future use of tumor infiltrating lymphocytes (TILs) in the treatment of melanoma. Fischkoff says the goal of Lion Biotechnologies is to utilize a central manufacturing facility where medical professionals can submit tumor samples of their patients, and received the proper TIL-based treatment back from the manufacturing facility.
Fischkoff says that while TILs have been researched in numerous amounts of cancers, the most advanced and concrete research has come from the melanoma field, specifically metastatic malignant melanoma. He adds that in trials where patients with melanoma have been treated with TIL-based treatments, response rates have been consistently "around 40% and even as high as 50%."
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
